公开(公告)号：US09556200B2

公开(公告)日：2017-01-31

申请号：US14381347

申请日：2013-03-06

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Tomokazu Kusumoto ,  Shigekazu Sasaki ,  Hironobu Maezaki

IPC分类号： A61K31/55 ,  C07D487/06 ,  C07D495/06 ,  C07D491/06

CPC分类号： C07D495/06 ,  C07D487/06 ,  C07D491/06

摘要： The present invention provides a compound having a superior serotonin 5-HT2C receptor activating action.The present invention relates to a compound represented by the formula (1) wherein ring A is an aromatic carbocycle optionally having substituent(s) or an aromatic heterocycle optionally having substituent(s), X is —N(R1)—, —O— or the like, when ring A is an aromatic carbocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), or the like, and when ring A is an aromatic heterocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), or the like, is a single bond or a double bond, and n is an integer of 0, 1 or 2, or a salt thereof.

摘要翻译： 本发明提供具有优良的5-羟色胺5-HT 2c受体激活作用的化合物。 本发明涉及由式（1）表示的化合物，其中环A是任选具有取代基的芳族碳环或任选具有取代基的芳族杂环，X是-N（R 1） - ， - O - 当环A为任选具有取代基的芳族碳环，则R 1为氢原子，任选具有取代基的烷基等，当环A为任选的芳香族杂环时， 具有取代基，则R 1为氢原子，任选具有取代基的烷基，任选具有取代基的环烷基等为单键或双键，n为 0,1或2的整数，或其盐。

公开(公告)号：US09624170B2

公开(公告)日：2017-04-18

申请号：US15108000

申请日：2014-12-25

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Tatsuki Koike ,  Makoto Fushimi ,  Jumpei Aida ,  Shuhei Ikeda ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Hidekazu Tokuhara

IPC分类号： C07D207/273 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D471/04 ,  C07D405/12 ,  C07D417/14 ,  C07D417/12 ,  C07D413/12 ,  C07D403/04 ,  C07D401/14

CPC分类号： C07D207/273 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

摘要： The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09085578B2

公开(公告)日：2015-07-21

申请号：US14379343

申请日：2013-02-19

申请人： Takeda Pharmaceutical Company Limited

发明人： Hiroyuki Nagamiya ,  Masato Yoshida ,  Masaki Seto ,  Shogo Marui ,  Tsuneo Oda ,  Yuji Ishichi ,  Hideo Suzuki ,  Tomokazu Kusumoto ,  Takatoshi Yogo ,  Chul Yun Rhim ,  Cheolhwan Yoon ,  Gil Nam Lee ,  Hyun Bin Kang ,  Kwang Ok Kim ,  Hye Sun Jeon

IPC分类号： C07D401/14 ,  A61K31/437 ,  C07D471/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  C07D519/00

摘要： The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

摘要翻译： 本发明提供了一种用于预防或治疗自身免疫性疾病（例如牛皮癣，类风湿性关节炎，炎性肠病，干燥综合征，白塞病，多发性硬化，系统性红斑狼疮等）等，其具有优异的Tyk2 抑制作用。 本发明涉及由下式表示的化合物，其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US10106556B2

公开(公告)日：2018-10-23

申请号：US15563161

申请日：2016-03-29

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Shuhei Ikeda ,  Tatsuki Koike ,  Jumpei Aida ,  Makoto Fushimi ,  Tomokazu Kusumoto ,  Hideyuki Sugiyama ,  Masako Miyazaki ,  Hidekazu Tokuhara ,  Yasushi Hattori ,  Makoto Kamata

IPC分类号： C07D498/04 ,  C07D413/14 ,  C07D401/06 ,  C07D413/06 ,  C07D417/14 ,  C07D471/04 ,  C07D401/10 ,  C07D413/10 ,  C12N9/99 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/538 ,  A61K31/5383

摘要： The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20150045351A1

公开(公告)日：2015-02-12

申请号：US14381347

申请日：2013-03-06

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Tomokazu Kusumoto ,  Shigekazu Sasaki ,  Hironobu Maezaki

IPC分类号： C07D495/06 ,  C07D491/06 ,  C07D487/06

CPC分类号： C07D495/06 ,  C07D487/06 ,  C07D491/06

摘要： The present invention provides a compound having a superior serotonin 5-HT2C receptor activating action.The present invention relates to a compound represented by the formula (1) wherein ring A is an aromatic carbocycle optionally having substituent(s) or an aromatic heterocycle optionally having substituent(s), X is —N(R1)—, —O— or the like, when ring A is an aromatic carbocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), or the like, and when ring A is an aromatic heterocycle optionally having substituent(s), then R1 is a hydrogen atom, an alkyl group optionally having substituent(s), a cycloalkyl group optionally having substituent(s), or the like, is a single bond or a double bond, and n is an integer of 0, 1 or 2, or a salt thereof.

摘要翻译： 本发明提供具有优良的5-羟色胺5-HT 2C受体激活作用的化合物。 本发明涉及由式（1）表示的化合物，其中环A是任选具有取代基的芳族碳环或任选具有取代基的芳族杂环，X是-N（R 1） - ，-O- 当环A是任选具有取代基的芳族碳环，则R1是氢原子，任选具有取代基的烷基等，当环A是任选具有取代基的芳族杂环时， 那么R 1是氢原子，任选具有取代基的烷基，任选具有取代基的环烷基等是单键或双键，n是整数 0,1或2，或其盐。

公开(公告)号：US20150045349A1

公开(公告)日：2015-02-12

申请号：US14379343

申请日：2013-02-19

申请人： Takeda Pharmaceutical Company Limited

发明人： Hiroyuki Nagamiya ,  Masato Yoshida ,  Masaki Seto ,  Shogo Marui ,  Tsuneo Oda ,  Yuji Ishichi ,  Hideo Suzuki ,  Tomokazu Kusumoto ,  Takatoshi Yogo ,  Chul Yun Rhim ,  Cheolhwan Yoon ,  Gil Nam Lee ,  Hyun Bin Kang ,  Kwang Ok Kim ,  Hye Sun Jeon

IPC分类号： C07D471/04

CPC分类号： C07D471/04 ,  C07D519/00

摘要： The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.